FRI0301 Assessment of the Effect of 12 Months Administration of Denosumab in Patients with Rheumatic...
FRI0301 Assessment of the Effect of 12 Months Administration of Denosumab in Patients with Rheumatic Diseases – Bone Mineral Density Increase in Lumbar Spine is Negatively Correlated with Baseline Oral Prednisolone Dose and Predicted by Decreasing Rate of Serum Undercarboxylated Osteocalcin at 6 Months
About this item
Full title
Author / Creator
Ebina, K. , Hashimoto, J. , Hirao, M. , Hagihara, K. , Noguchi, T. and Yoshikawa, H.
Publisher
Kidlington: Elsevier Limited
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: Elsevier Limited
More information
Scope and Contents
Contents
BackgroundReceptor activator of nuclear factor kappa-B ligand (RANKL) is a key inducer of osteoclast differentiation and activation, which plays a crucial role in osteoporosis and bone erosion of rheumatic diseases. Denosumab (DSM) is an anti-RANKL antibody approved for the treatment of postmenopausal osteoporosis, while its effect in rheumatic dis...
Alternative Titles
Full title
FRI0301 Assessment of the Effect of 12 Months Administration of Denosumab in Patients with Rheumatic Diseases – Bone Mineral Density Increase in Lumbar Spine is Negatively Correlated with Baseline Oral Prednisolone Dose and Predicted by Decreasing Rate of Serum Undercarboxylated Osteocalcin at 6 Months
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1901773004
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1901773004
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/annrheumdis-2015-eular.2658
